Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Relmada Therapeutics (NASDAQ:RLMD) reported its Q4 earnings results on Tuesday, March 19, 2024 at 04:15 PM.
Here's what investors need to know about the announcement.
Relmada Therapeutics missed estimated earnings by -1.0%, reporting an EPS of $-0.84 versus an estimate of $-0.83.
Revenue was down $0 from the same period last year.
Last quarter the company beat on EPS by $0.18 which was followed by a 0.0% increase in the share price the next day.
To track all earnings releases for Relmada Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: RLMD